Clinical Trials Browser

Neoplasms × Plasma cell × 90 days × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT00352924 2026-03-06

Agriculture Health Study

Active not recruiting

89,655 enrolled

GenitourinaryLymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

NCT03844048 2026-03-06

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

165 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05866757 2026-03-04

Discontinuation Study

Phase NA Recruiting

70 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Phase 1/2 Recruiting

130 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT00900198 2026-02-20

Collection of Tissue Samples for Cancer Research

Recruiting

5,000 enrolled

LymphoidMyeloidPlasma cell

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

514 enrolled

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

440 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT07409246 2026-02-13

A Study to Evaluate the, Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Phase 1 Not yet recruiting

127 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT05650632 2026-02-12

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

210 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT07290309 2026-01-21

SURGE

Phase NA Recruiting

300 enrolled

BreastGastrointestinalGynecologicLymphoidPlasma cell

Breast Neoplasms, Colonic Neoplasms, Lymphoma, Motor Activity, Multiple Myeloma, Neoplasms, Ovarian Neoplasms

NCT07226934 2026-01-08

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Communication, Lymphoma, Multiple Myeloma, Neoplasms

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07071909 2026-01-06

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT07102212 2025-12-24

FOCUS

Phase NA Not yet recruiting

120 enrolled

BreastDermatologicGenitourinaryPlasma cellThoracic

Alzheimer Disease, Anxiety Disorders, Breast Neoplasms, Depression, Fatigue, Lung Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

NCT04952766 2025-12-23

EREVA

Phase 4 Completed

196 enrolled

Other hematologic neoplasmPlasma cell

Acquired Immunodeficiency Syndrome, Diabetes Mellitus, Type 2, Hypergammaglobulinemia, Multiple Sclerosis, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

Clinical Trials

TAPUR

Agriculture Health Study

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Discontinuation Study

DETERMINE

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Collection of Tissue Samples for Cancer Research

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

SELECT-CAR-NK

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

A Study to Evaluate the, Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

SURGE

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

FOCUS

EREVA